Core Viewpoint - Investors are expected to focus on the sales performance of Amarin Corporation's sole marketed drug, Vascepa/Vazkepa, during the upcoming Q2 2025 results announcement, with a consensus estimate of $45.2 million in revenue and a loss of 60 cents per share [1][5]. Group 1: Sales Performance - Vascepa is approved in the U.S. for treating severe hypertriglyceridemia and reducing cardiovascular event risks, and in the EU as Vazkepa for the same indications [2]. - U.S. sales of Vascepa are likely to have declined in Q2 2025 due to increasing generic competition, while EU sales of Vazkepa are expected to have increased significantly, particularly in the UK and Spain [3][5]. Group 2: Cost Management and Financial Position - Amarin has restructured its commercial infrastructure in Europe to align with pricing and reimbursement, which may have contributed to a decline in operating expenses due to cost optimization efforts [4][5]. - The company signed a long-term license and supply agreement with Recordati for Vazkepa across 59 EU countries, which includes an upfront payment of $25 million and potential milestone payments of up to $150 million, likely enhancing Amarin's cash position and projected to deliver approximately $70 million in cost savings over the next year [6][7]. Group 3: Earnings Surprise History - Amarin has a mixed earnings surprise history, beating estimates in two of the last four quarters, meeting once, and missing once, with an average surprise of 29.11% [8]. - The company currently has an Earnings ESP of 0.00% as both the Most Accurate Estimate and Zacks Consensus Estimate are at a loss of 60 cents per share, with a Zacks Rank of 1 (Strong Buy) [10].